Wai Yuen Tong Medicine Holdings Limited (0897.HK)
HKD 0.21
(-0.48%)
HKD 0.21
(-0.48%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 113.79 Million HKD | -20.99% |
| 2022 | 115.88 Million HKD | 0.39% |
| 2021 | 154.61 Million HKD | 136.6% |
| 2020 | -107.43 Million HKD | 418.4% |
| 2019 | 605.44 Million HKD | 77.28% |
| 2018 | 161.57 Million HKD | -47.63% |
| 2017 | -49.14 Million HKD | 41.55% |
| 2016 | -65.19 Million HKD | -91.17% |
| 2015 | 58.81 Million HKD | -158.23% |
| 2014 | 146.59 Million HKD | -34.52% |
| 2013 | 152.34 Million HKD | -8.23% |
| 2012 | 167.71 Million HKD | 183.95% |
| 2011 | -197.75 Million HKD | -243.4% |
| 2010 | 137.9 Million HKD | 52.88% |
| 2009 | 35.92 Million HKD | -69.92% |
| 2008 | -256.81 Million HKD | 241.89% |
| 2007 | 131.12 Million HKD | 954.92% |
| 2006 | 8.31 Million HKD | 125.46% |
| 2005 | -32.66 Million HKD | 9.79% |
| 2004 | -14.97 Million HKD | -299.34% |
| 2003 | -9.06 Million HKD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 Q2 | 120.72 Million HKD | 0.0% |
| 2023 FY | - HKD | -20.99% |
| 2023 Q4 | 10.49 Million HKD | 0.0% |
| 2022 Q2 | 63.25 Million HKD | 0.0% |
| 2022 FY | - HKD | 0.39% |
| 2022 Q4 | 101.34 Million HKD | 0.0% |
| 2021 Q4 | 82.86 Million HKD | 0.0% |
| 2021 FY | - HKD | 136.6% |
| 2021 Q2 | 84.95 Million HKD | 0.0% |
| 2020 Q4 | 45.61 Million HKD | 0.0% |
| 2020 Q2 | 23.91 Million HKD | 0.0% |
| 2020 FY | - HKD | 418.4% |
| 2019 FY | - HKD | 77.28% |
| 2019 Q4 | -391 Thousand HKD | 0.0% |
| 2019 Q2 | -13.07 Million HKD | 0.0% |
| 2018 FY | - HKD | -47.63% |
| 2018 Q4 | -43.32 Million HKD | 0.0% |
| 2018 Q2 | -52.49 Million HKD | 0.0% |
| 2017 Q2 | -28.86 Million HKD | 0.0% |
| 2017 Q4 | -36.04 Million HKD | 0.0% |
| 2017 FY | - HKD | 41.55% |
| 2016 Q4 | -63.33 Million HKD | 0.0% |
| 2016 Q2 | -47.71 Million HKD | 0.0% |
| 2016 FY | - HKD | -91.17% |
| 2015 Q2 | -36.81 Million HKD | 0.0% |
| 2015 Q4 | -21.27 Million HKD | 0.0% |
| 2015 FY | - HKD | -158.23% |
| 2014 Q2 | -22.67 Million HKD | -146.77% |
| 2014 FY | - HKD | -34.52% |
| 2014 Q3 | 36.7 Million HKD | 261.87% |
| 2014 Q4 | 36.7 Million HKD | 0.0% |
| 2014 Q1 | 48.47 Million HKD | 0.0% |
| 2013 FY | - HKD | -8.23% |
| 2013 Q4 | 48.47 Million HKD | 0.0% |
| 2013 Q3 | 48.47 Million HKD | 102.71% |
| 2013 Q2 | 23.91 Million HKD | -43.06% |
| 2013 Q1 | 41.99 Million HKD | 0.0% |
| 2012 Q1 | -49.45 Million HKD | 0.0% |
| 2012 Q2 | -49.45 Million HKD | 0.0% |
| 2012 Q3 | 41.99 Million HKD | 184.92% |
| 2012 Q4 | 41.99 Million HKD | 0.0% |
| 2012 FY | - HKD | 183.95% |
| 2011 Q1 | 33.03 Million HKD | 0.0% |
| 2011 FY | - HKD | -243.4% |
| 2011 Q4 | -49.45 Million HKD | 0.0% |
| 2011 Q3 | -49.45 Million HKD | -249.71% |
| 2011 Q2 | 33.03 Million HKD | 0.0% |
| 2010 Q4 | 33.03 Million HKD | 0.0% |
| 2010 FY | - HKD | 52.88% |
| 2010 Q1 | 17.15 Million HKD | 0.0% |
| 2010 Q2 | 17.15 Million HKD | 0.0% |
| 2010 Q3 | 33.03 Million HKD | 92.56% |
| 2009 Q1 | -81.25 Million HKD | 0.0% |
| 2009 Q2 | -81.25 Million HKD | 0.0% |
| 2009 Q3 | 17.15 Million HKD | 121.11% |
| 2009 FY | - HKD | -69.92% |
| 2009 Q4 | 17.15 Million HKD | 0.0% |
| 2008 Q2 | 25.94 Million HKD | 0.0% |
| 2008 Q4 | -81.25 Million HKD | 0.0% |
| 2008 Q3 | -81.25 Million HKD | -413.22% |
| 2008 Q1 | 25.94 Million HKD | 0.0% |
| 2008 FY | - HKD | 241.89% |
| 2007 Q2 | 6.7 Million HKD | 0.0% |
| 2007 Q1 | 6.7 Million HKD | 0.0% |
| 2007 FY | - HKD | 954.92% |
| 2007 Q4 | 25.94 Million HKD | 0.0% |
| 2007 Q3 | 25.94 Million HKD | 286.75% |
| 2006 Q3 | 6.7 Million HKD | 129.18% |
| 2006 Q2 | -22.98 Million HKD | 0.0% |
| 2006 Q1 | -22.98 Million HKD | 0.0% |
| 2006 FY | - HKD | 125.46% |
| 2006 Q4 | 6.7 Million HKD | 0.0% |
| 2005 Q3 | -22.98 Million HKD | -79.0% |
| 2005 FY | - HKD | 9.79% |
| 2005 Q1 | -12.84 Million HKD | 0.0% |
| 2005 Q2 | -12.84 Million HKD | 0.0% |
| 2005 Q4 | -22.98 Million HKD | 0.0% |
| 2004 Q4 | -12.84 Million HKD | 0.0% |
| 2004 Q1 | -1.77 Million HKD | 0.0% |
| 2004 FY | - HKD | -299.34% |
| 2004 Q3 | -12.84 Million HKD | -625.18% |
| 2004 Q2 | -1.77 Million HKD | 0.0% |
| 2003 Q3 | -1.77 Million HKD | 0.0% |
| 2003 FY | - HKD | 0.0% |
| 2003 Q4 | -1.77 Million HKD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 150.4 Million HKD | 24.336% |
| Grand Pharmaceutical Group Limited | 2.96 Billion HKD | 96.164% |
| Extrawell Pharmaceutical Holdings Limited | -129.51 Million HKD | 187.861% |
| Qianhai Health Holdings Limited | -50.22 Million HKD | 326.558% |
| Lee's Pharmaceutical Holdings Limited | 109.82 Million HKD | -3.622% |
| Essex Bio-Technology Limited | 418.37 Million HKD | 72.8% |
| Tongfang Kontafarma Holdings Limited | 76.63 Million HKD | -48.497% |
| PuraPharm Corporation Limited | -26.16 Million HKD | 534.858% |
| SSY Group Limited | 2.11 Billion HKD | 94.618% |
| JBM (Healthcare) Limited | 204.39 Million HKD | 44.323% |
| Jacobson Pharma Corporation Limited | 429.92 Million HKD | 73.53% |
| China Resources Pharmaceutical Group Limited | 15.43 Billion HKD | 99.263% |